Evidence map›Paper›PMID 27709814›Full record

ArticleProteomics2017

Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics.

Mariette Matondo, Marlène Marcellin, Karima Chaoui, Marie-Pierre Bousquet-Dubouch, Anne Gonzalez-de-Peredo, Bernard Monsarrat, Odile Burlet-Schiltz

Open access · hybridAbstract read
In one paragraph

Article in Proteomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mariette MatondoInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France.
Marlène MarcellinInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France.
Karima ChaouiInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France.
Marie-Pierre Bousquet-DubouchInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France.
Anne Gonzalez-de-PeredoInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France.
Bernard MonsarratInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France.
Odile Burlet-SchiltzInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France.
Université Fédérale de Toulouse Midi-Pyrénées · FRCentre National de la Recherche Scientifique · FRInstitut de Pharmacologie et de Biologie Structurale · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ubiquitin-proteasome pathway (UPP) plays a critical role in the degradation of proteins implicated in cell cycle control, signal transduction, DNA damage response, apoptosis and immune response. Proteasome inhibitors can inhibit the growth of a broad spectrum of human cancer cells by altering the balance of intracellular proteins. However, the targets of these compounds in acute myeloid leukemia (AML) cells have not been fully characterized. Herein, we combined large-scale quantitative analysis by SILAC-MS and targeted quantitative proteomic analysis in order to identify proteins regulated upon proteasome inhibition in two AML cell lines displaying different stages of maturation: immature KG1a cells and mature U937 cells. In-depth data analysis enabled accurate quantification of more than 7000 proteins in these two cell lines. Several candidates were validated by selected reaction monitoring (SRM) measurements in a large number of samples. Despite the broad range of proteins known to be affected by proteasome inhibition, such as heat shock (HSP) and cell cycle proteins, our analysis identified new differentially regulated proteins, including IL-32, MORF family mortality factors and apoptosis inducing factor SIVA, a target of p53. It could explain why proteasome inhibitors induce stronger apoptotic responses in immature AML cells.

Indexed as

Computational BiologyAcetylcysteineApoptosisApoptosis Regulatory ProteinsBortezomibCell CycleCell Cycle ProteinsCell DifferentiationCell Line, TumorGene Expression ProfilingGene Expression Regulation, LeukemicGene OntologyHeat-Shock ProteinsHumansInterleukinsLeukocytesAcetylcysteineApoptosis Regulatory Proteinsbenzyloxycarbonylleucyl-leucyl-leucine aldehydeBortezomibCell Cycle ProteinsHeat-Shock ProteinsIL32 protein, humanInterleukinslactacystinLeupeptinsMORF4 protein, humanProteasome Endopeptidase ComplexProteasome InhibitorsProtein IsoformsSIVA1 protein, humanTranscription FactorsTumor Suppressor Protein p53ApoptosisHuman acute myeloid leukemia (AML) cellsProteasome inhibitorSILACTargeted proteomicsTechnology

Identifiers

PMID27709814
PMCPMC5396343
OpenAlexW2528774899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.